Lung Cancer

Web Exclusives | June 23, 2021
Data indicate a steady improvement over the past decade in NSCLC survival rates due to immunotherapy and targeted therapy.
Web Exclusives | June 23, 2021
A recent review article provided best practices for biomarker testing and recommendations for the diagnosis and management of patients with advanced NSCLC.
Web Exclusives | June 23, 2021
Treatment timing and type at time of diagnosis of stage III NSCLC influences patients’ overall survival, with gender and race differences also influencing therapy.
Web Exclusives | June 23, 2021
Data from the CodeBreaK 100 NSCLC subset population prompted the FDA to grant accelerated approval for sotorasib for patients with KRASG12C-mutated NSCLC.
Web Exclusives | May 27, 2021
The American Cancer Society Cancer Action Network has published data that demonstrate there are multiple barriers to biomarker testing access and released recommendations that address these barriers.
Web Exclusives | May 27, 2021
Sotorasib has shown promising antitumor activity in phase 2 of a clinical trial of patients with heavily treated advanced NSCLC.
Web Exclusives | May 27, 2021
Recently released survey responses identified multiple barriers to, and dissatisfaction with, the current state of molecular testing in lung cancer.
Web Exclusives | May 27, 2021
An investigational treatment for second-line treatment of NSCLC was found to be well tolerated and active against KRAS mutations, according to the results of a new study.
Web Exclusives | April 2, 2021
To ensure optimal treatment selection and outcomes, differentiating between COVID-19 infection and interstitial lung disease is critical.
Web Exclusives | April 2, 2021
Efficacy of osimertinib as adjuvant therapy was demonstrated in ADAURA, a randomized, double-blind, placebo-controlled trial.
Page 13 of 23
Results 121 - 130 of 230

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country